Molnunat
In brief
- In our pharmacy, you can buy Molnunat with a prescription, with delivery in 9–21 days throughout your region. Discreet and anonymous packaging.
- Molnunat is used to treat mild-to-moderate COVID-19 in high-risk adults. It works by inhibiting viral replication through introduction of errors in the SARS-CoV-2 RNA genome.
- The usual dose is 800mg (four 200mg capsules) taken twice daily.
- The form of administration is an oral capsule.
- The effect begins within 2–4 hours after the first dose.
- The total treatment duration is 5 days, with each dose maintaining antiviral activity for approximately 12 hours.
- Avoid alcohol consumption during treatment.
- The most common side effects include diarrhoea, nausea, headache, and dizziness.
- Would you like to try Molnunat without a prescription?
Basic Molnunat information
| Attribute | Information |
|---|---|
| INN (International Nonproprietary Name) | Molnupiravir |
| Brand names (UK) | Lagevrio™ |
| ATC Code | J05AB18 (Antivirals for systemic use) |
| Forms and strengths | 200mg capsules |
| Manufacturer (UK) | MSD (Merck Sharp & Dohme) |
| Registration status | Conditional marketing authorisation (MHRA) |
| Classification | Prescription-only (Rx) |
Molnupiravir – licensed in the UK as Lagevrio® – is an oral capsule formulation designed for specific COVID-19 cases. Its conditional marketing authorisation means this treatment undergoes continuous safety evaluation by the Medicines and Healthcare products Regulatory Agency. Molnunat is not licensed in the UK; the licensed UK brand of molnupiravir is MSD's Lagevrio.
Each carton contains 40 capsules for a complete 5-day regimen packaged in blister strips. You'll need an NHS or private prescription from your healthcare provider since capsule availability remains strictly regulated. The authorisation covers usage across England, Scotland, Wales and Northern Ireland.
How molnupiravir attacks viruses
The pharmacology of molnupiravir centres on unique antiviral action. Unlike conventional treatments, it converts to an active compound called β-D-N4-hydroxycytidine triphosphate inside your body. This molecular mimic inserts errors into SARS-CoV-2's RNA structure during replication.
When the virus attempts to copy itself, these accumulating mutations create a "viral error catastrophe" that halts spread. Clinical pharmacology studies show peak blood concentration occurs approximately 1.5 hours after swallowing capsules. With a half-life of 3.3 hours, molnupiravir clears relatively quickly through renal pathways.
UK prescribing information notes minimal metabolic interactions through liver enzymes. No cytochrome P450 interference occurs, though caution remains with immunosuppressant combinations. Interactions with alcohol have not been formally studied.
Approved medical uses and restrictions
Healthcare professionals may prescribe molnupiravir capsules for a specific patient group exhibiting mild-to-moderate COVID-19 symptoms. Authorised use requires meeting all criteria:
- Adults aged 18+ with at least one high-risk factor (e.g., obesity, chronic kidney disease, diabetes, heart conditions)
- Treatment started within 5 days of symptom onset
- Positive SARS-CoV-2 test confirmation
- Ambulatory patients not requiring hospital oxygen therapy
UK dispensaries cannot supply capsules for off-label applications. Hospitalisation prevention studies show limited effectiveness compared to alternatives. In clinical trials, molnupiravir reduced the risk of hospitalisation or death by about 30% versus placebo. Using capsules for post-exposure prevention or severe infection shows no demonstrated benefit and is medically contraindicated.
Absolute contraindications include pregnancy due to demonstrated embryotoxicity in animal reproductive studies. Under-18 usage remains unauthorised pending paediatric investigation plans. Breastfeeding safety data are insufficient, so breastfeeding is not recommended during treatment.
Taking molnupiravir correctly
| Clinical scenario | Capsule strength | Regimen |
|---|---|---|
| COVID-19 (high-risk adults) | 200mg capsules | 4 capsules twice daily for 5 days |
Swallow molnupiravir capsules whole without chewing or crushing around 12 hours apart. While food doesn't affect absorption, coordinating dosing schedules with meals often aids adherence. UK package leaflets explicitly state discontinuation risks if completing the 40-capsule regimen proves impossible.
Pharmacokinetic studies show no required modification concerning elderly patients. Pharmaceutical consultations should note that liver or kidney impairment data remains sparse. Store the capsules in their moisture-proof blisters at room temperature; refrigeration is not needed.
Missing capsules requires careful guidance: take the forgotten dose immediately unless approaching the next scheduled administration. Doubling capsules to compensate increases adverse event likelihood. Return any leftover capsules to a pharmacy for safe disposal.
Contraindications and safety warnings
Molnunat carries absolute contraindications in specific circumstances. Pregnancy remains the paramount restriction due to established embryotoxicity risks observed in animal studies. Use in those under 18 years is prohibited, as safety data in children and adolescents are unavailable. Anyone with known severe allergy or hypersensitivity to molnupiravir or capsule ingredients must avoid treatment.
Common side effects include diarrhoea (affecting around 13% of users), nausea (approximately 8%) and dizziness (about 3%). These symptoms are often manageable without treatment discontinuation. Clinicians note rare instances of hypersensitivity reactions requiring immediate cessation.
Key precautions apply for immunocompromised patients and those managing multiple chronic conditions. Enhanced monitoring is recommended during treatment. Bone and cartilage health considerations exist theoretically - though human evidence remains limited - advising specialist review where risks outweigh benefits.
Alternatives comparison
| Drug | Hospitalisation risk reduction | Key prescribing factor |
|---|---|---|
| Paxlovid (nirmatrelvir/ritonavir) | ~89% | Significant medication interactions impacting suitability |
| Sotrovimab (xevudy) | ~79% | IV administration limits accessibility |
| Molnupiravir (Lagevrio) | ~30% | Lower drug interaction profile advantageous when polypharmacy exists |
The UK antivirals protocol generally positions Paxlovid as first-line where clinically appropriate, with molnupiravir as an alternative when interactions preclude nirmatrelvir/ritonavir use or intravenous therapies aren't viable.
Guidelines for proper use
Correct administration of molnupiravir significantly impacts treatment outcomes. Adherence to these evidence-based protocols ensures safety and effectiveness:
Dosing protocol
- Schedule: Four 200mg capsules taken twice daily (approximately 12 hours apart)
- Duration: Complete 5-day course without extension
- Critical window: Initiate therapy within 5 days of symptom onset
Administration guidance
Swallow capsules whole with adequate water. Can be taken with or without food, though taking with light meals may reduce potential nausea. Alcohol consumption during treatment hasn't been systematically studied - discuss with prescribing clinician.
Storage and disposal
Maintain capsules in original blister packaging at room temperature (20-25°C). Storage above 30°C may compromise stability. Never use damaged capsules showing powder leakage. Return any unused medication to community pharmacies for safe disposal after completing treatment - do not store leftover capsules.
Adherence support
Set phone reminders for consistent 12-hour intervals between doses. Complete entire course even if symptoms improve earlier - partial treatment risks viral rebound. If managing multiple medications, utilise pill organisers with clear AM/PM compartments. Report any adverse effects to your GP immediately via NHS services.
